• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板与淋巴细胞比值及中性粒细胞与淋巴细胞比值可预测肝癌患者的肿瘤大小及生存情况:一项回顾性研究

Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study.

作者信息

Suner Aslı, Carr Brian I

出版信息

Ann Med Surg (Lond). 2020 Sep 6;58:167-171. doi: 10.1016/j.amsu.2020.08.042. eCollection 2020 Oct.

DOI:10.1016/j.amsu.2020.08.042
PMID:32994979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7501491/
Abstract

BACKGROUND

Inflammation is a recognized concomitant of hepatocellular carcinoma (HCC) and its indices are prognostically useful.

AIMS

To evaluate two commonly used inflammatory indices, neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), to examine their relationship to maximum tumor diameter (MTD) and to survival.

METHODS

A database of 1024 prospectively-accrued HCC patients was examined, who had full baseline tumor parameter data, including CT scan information on HCC size and whose survival was known. Analyses of NLR and PLR were correlated to MDT and to survival. NLR and PLR cutoffs were calculated from receiver operator characteristic curves.

RESULTS

Every MTD pair had significantly different PLR values, for MTD groups of groups <2/≥2, <3/≥3, <4/≥4, <5/≥5 cm. However there were few significant differences in NLR values. Logistic regression models of different MTD groups likewise showed significance for PLR. Patients with both low NLR and low PLR had the longest overall survival compared to all the other 3 combinations of NLR and PLR. In a Cox regression analysis, univariate models on NLR (≤3.02/>3.02) and PLR (≤6.82/>6.82) groups, showed significance for PLR, p = 0.034 and approaching significance for NLR, p = 0.057.

CONCLUSIONS

MTD pairs down to <2/≥2 cm showed significance for PLR, survival showed significance for PLR and almost for NLR.

摘要

背景

炎症是肝细胞癌(HCC)公认的伴随症状,其指标具有预后价值。

目的

评估两种常用的炎症指标,即中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),以研究它们与最大肿瘤直径(MTD)及生存率的关系。

方法

对一个包含1024例前瞻性纳入的HCC患者的数据库进行研究,这些患者拥有完整的基线肿瘤参数数据,包括关于HCC大小的CT扫描信息且其生存情况已知。对NLR和PLR进行分析,并与MTD及生存率进行相关性研究。通过受试者工作特征曲线计算NLR和PLR的临界值。

结果

对于MTD分组为<2/≥2 cm、<3/≥3 cm、<4/≥4 cm、<5/≥5 cm的各组,每一对MTD对应的PLR值均存在显著差异。然而,NLR值的显著差异较少。不同MTD组的逻辑回归模型同样显示PLR具有显著性。与NLR和PLR的其他3种组合相比,NLR和PLR均低的患者总生存期最长。在Cox回归分析中,NLR(≤3.02/>3.02)和PLR(≤6.82/>6.82)分组的单变量模型显示PLR具有显著性,p = 0.034,NLR接近显著性,p = 0.057。

结论

低至<2/≥2 cm的MTD对PLR具有显著性,生存率对PLR具有显著性,对NLR几乎也具有显著性。

相似文献

1
Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study.血小板与淋巴细胞比值及中性粒细胞与淋巴细胞比值可预测肝癌患者的肿瘤大小及生存情况:一项回顾性研究
Ann Med Surg (Lond). 2020 Sep 6;58:167-171. doi: 10.1016/j.amsu.2020.08.042. eCollection 2020 Oct.
2
The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合应用于接受经动脉化疗栓塞治疗的肝细胞癌患者的预后及预测价值。
Cancer Manag Res. 2019 Feb 12;11:1391-1400. doi: 10.2147/CMAR.S190545. eCollection 2019.
3
C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma.C 反应蛋白和血小板淋巴细胞比值可作为低甲胎蛋白肝细胞癌的潜在肿瘤标志物。
Oncology. 2019;96(1):25-32. doi: 10.1159/000492473. Epub 2018 Oct 18.
4
The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对四肢巨细胞瘤的预后意义。
BMC Cancer. 2019 Apr 8;19(1):329. doi: 10.1186/s12885-019-5511-x.
5
Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics.炎症标志物C反应蛋白和血小板与淋巴细胞比值与肝癌特征的关系。
J Transl Sci. 2019 Jun;5(3). doi: 10.15761/JTS.1000260. Epub 2018 Jun 22.
6
Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma.术后中性粒细胞与淋巴细胞比值联合血小板与淋巴细胞比值可预测肝细胞癌患者的预后。
J Surg Res. 2015 Sep;198(1):73-9. doi: 10.1016/j.jss.2015.05.003. Epub 2015 May 7.
7
Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation.基于中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的列线图预测肝癌患者射频消融术后复发。
Cardiovasc Intervent Radiol. 2021 Oct;44(10):1551-1560. doi: 10.1007/s00270-021-02872-8. Epub 2021 May 25.
8
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对接受抗 PD-1 治疗的晚期肝细胞癌患者的预测价值。
Cancer Med. 2020 Jul;9(14):4962-4970. doi: 10.1002/cam4.3135. Epub 2020 May 18.
9
Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC.术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)作为可切除肝癌预后不良的指标。
PeerJ. 2019 Oct 14;7:e7132. doi: 10.7717/peerj.7132. eCollection 2019.
10
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值可预测 DEB-TACE 后肝癌患者的肿瘤反应。
Eur Radiol. 2020 Oct;30(10):5663-5673. doi: 10.1007/s00330-020-06931-5. Epub 2020 May 19.

引用本文的文献

1
Factors Relating to Tumor Size and Survival in Patients with Hepatocellular Carcinoma: Significance of Platelet-Lymphocyte Ratio, Portal Vein Thrombosis, and Albumin.肝细胞癌患者肿瘤大小与生存的相关因素:血小板-淋巴细胞比值、门静脉血栓形成及白蛋白的意义
Oncology. 2025 Apr 8:1-11. doi: 10.1159/000545636.
2
Correlation between the white blood cell/platelet ratio and 28-day all-cause mortality in cardiac arrest patients: a retrospective cohort study based on machine learning.心脏骤停患者白细胞/血小板比值与28天全因死亡率的相关性:一项基于机器学习的回顾性队列研究
Front Pharmacol. 2025 Jan 7;15:1527664. doi: 10.3389/fphar.2024.1527664. eCollection 2024.
3
Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.瑞戈非尼联合免疫检查点抑制剂加或不加经动脉化疗栓塞术作为晚期肝细胞癌二线治疗的疗效和安全性:一项倾向评分匹配分析
J Hepatocell Carcinoma. 2023 Feb 27;10:303-313. doi: 10.2147/JHC.S399135. eCollection 2023.
4
Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.炎症和营养标志物在晚期胃癌围手术期的预后意义。
BMC Cancer. 2023 Jan 3;23(1):5. doi: 10.1186/s12885-022-10479-6.
5
An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments.中性粒细胞与淋巴细胞比值升高预示肝癌介入治疗后患者预后不良。
Biomed Res Int. 2022 Nov 25;2022:6141317. doi: 10.1155/2022/6141317. eCollection 2022.
6
Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.瑞戈非尼联合PD-1阻断免疫疗法与瑞戈非尼作为晚期肝细胞癌二线治疗的多中心回顾性研究
J Hepatocell Carcinoma. 2022 Mar 10;9:157-170. doi: 10.2147/JHC.S353956. eCollection 2022.
7
A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients.血液淋巴细胞和 AST 水平的联合检测可区分小肝细胞癌患者和非癌症患者。
J Gastrointest Cancer. 2021 Dec;52(4):1211-1216. doi: 10.1007/s12029-021-00740-9. Epub 2021 Nov 11.

本文引用的文献

1
Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.中性粒细胞与淋巴细胞比值的动态变化预测接受经动脉化疗栓塞的肝细胞癌患者的预后。
Cancer Manag Res. 2020 May 14;12:3433-3444. doi: 10.2147/CMAR.S245396. eCollection 2020.
2
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib.中性粒细胞与淋巴细胞比值在索拉非尼治疗的肝癌患者中识别长期生存者的效用。
Medicine (Baltimore). 2020 May 29;99(22):e19958. doi: 10.1097/MD.0000000000019958.
3
Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma.全身炎症标志物在新诊断、未经治疗的肝细胞癌中的临床意义
Cancers (Basel). 2020 May 21;12(5):1300. doi: 10.3390/cancers12051300.
4
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对接受抗 PD-1 治疗的晚期肝细胞癌患者的预测价值。
Cancer Med. 2020 Jul;9(14):4962-4970. doi: 10.1002/cam4.3135. Epub 2020 May 18.
5
The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization.中性粒细胞与淋巴细胞比值是接受经动脉化疗栓塞的肝细胞癌患者生存的一个预测因素。
Ann Transl Med. 2020 Apr;8(8):541. doi: 10.21037/atm.2020.02.113.
6
Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis.经动脉化疗栓塞治疗肝细胞癌中炎症指标的预后意义:系统评价和荟萃分析。
PLoS One. 2020 Mar 26;15(3):e0230879. doi: 10.1371/journal.pone.0230879. eCollection 2020.
7
Inflammatory Mechanisms of HCC Development.肝癌发生的炎症机制
Cancers (Basel). 2020 Mar 10;12(3):641. doi: 10.3390/cancers12030641.
8
Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma.索拉非尼治疗的肝细胞癌中通过整合炎症评分的风险因素改善生存预测
Liver Cancer. 2019 Oct;8(5):387-402. doi: 10.1159/000492628. Epub 2018 Oct 4.
9
STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery.STROCSS 2019 指南:加强外科学队列研究报告。
Int J Surg. 2019 Dec;72:156-165. doi: 10.1016/j.ijsu.2019.11.002. Epub 2019 Nov 6.
10
Prognostic nutritional index is superior as a predictor of prognosis among various inflammation-based prognostic scores in patients with hepatocellular carcinoma after curative resection.在根治性切除术后的肝细胞癌患者中,预后营养指数作为一种预后预测指标,在各种基于炎症的预后评分中表现更优。
Hepatol Res. 2020 Jan;50(1):101-109. doi: 10.1111/hepr.13431. Epub 2019 Nov 14.